Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

pembrolizumab 2nilotinib 2avapritinib 2trastuzumab deruxtecan 1talquetamab 1pomalidomide 1montelukast 1lazertinib 1larotrectinib 1ivosidenib 1entrectinib 1dostarlimab 1daratumumab 1carfilzomib 1asciminib 1amivantamab 1Thalidomide 1TIC10 compound 1Prednisone 1Pemetrexed 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Diphenhydramine 1Dexamethasone 1Dasatinib 1Crizotinib 1Carboplatin 1Bortezomib 1Appointments and Schedules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Has announcements × ivosidenib × Clear all
NCT02074839 2025-06-08

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Servier

Phase 1 Recruiting
291 enrolled 3 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡